These findings do not erase the important benefits of GLP-1 drugs
During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n)
market only high-end skin care products, only use high-quality formulas, a strong team of research and scientists 4
Rumbel Professor for Healthy Aging Research Oregon State University Copyright 2002-2026 Linus Pauling Institute Figure Alternative Text Figure 1
In obese or diabetic individuals, this can be an issue
Any thoughts of self-harm or suicide require immediate medical attention